**Connecting the dots: how can statisticians drive end-to-end thinking in the development of new medicines?**

[This is a joint session between the HtA and Launch & Lifecycle eSIGs]

We statisticians contribute to the development and launch of new medicines in so many ways. We leverage real world evidence, literature data, and other data sources in addition to clinical trials to answer questions for internal decision making and external stakeholders including regulators, payers, physicians, and patients.

End-to-end thinking is increasingly important in the development and lifecycle of a medicine, in order to address both regulatory and non-regulatory needs. Evolving regulations from payers, higher pressure on prices, and bigger competition within and across indications for limited healthcare resources also put pressure on organizations to do things differently. Breaking down silos is one way we can tackle these challenges. If you want to share or improve your understanding of how regulatory, HTA, and medical affairs demands converge, this session is for you.

The session begins with a lightning round of 5-minute talks from statisticians with different specializations across the lifecycle. These short presentations, where presenters clarify their roles, set the scene.

Participants will then break out and discuss some case studies of “typical new products” intended to help identify and understand the challenges for statisticians from the different perspectives of regulatory, HTA, and medical affairs. The small group discussions will allow you to learn from your peers and get feedback on your own ideas and thoughts before feeding back to the larger group.

We hope that new and seasoned statisticians will enjoy this interactive session organized by the HTA and the Launch and Lifecycle special interest groups.